Nuvation Bio Inc. Class A Common Stock vs WD 40 Company — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $4.95 (market cap $1.71B), while WD 40 Company trades at $203.44 (market cap $2.71B). The key difference: WD 40 Company is the larger of the two by market cap, and WD 40 Company pays a 2.02% dividend while Nuvation Bio Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 0 Days and WD 40 Company for 22 Days on average.
| NUVB | WDFC | |
|---|---|---|
Market Cap | $1.71B | $2.71B |
Volume | 5,448,712 | 99,290 |
Sector | Health | Basic Materials |
52-Week High | $9.54 | $264.91 |
52-Week Low | $3.41 | $187.52 |
Typical Hold Time | 0 Days | 22 Days |
Enterprise Value | $1.30B | $2.76B |
Dividend Yield | — | 2.02% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
WD-40 Company (WDFC) trades at $201.50, down 1.31% on the day, with technical indicators showing a bearish trend. The company maintains strong fundamentals with 55.82% gross margins and 13.22% net income margin, though recent earnings showed mixed results with two beats and one miss. Analyst consensus is mixed with 71% hold ratings despite a $475 price target, while institutional buying activity remains active. Recent news highlights strategic growth initiatives including global expansion and new CFO leadership.
The stock presents a cautious outlook with strong profitability offset by premium valuations (P/E 30.64) and technical weakness. Upside potential exists from the significant analyst price target premium, but risks include margin pressure from input costs and execution challenges in international markets. Current levels near support at $198-200 may offer entry points for long-term investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →WD-40 Company is a global marketing organization dedicated to creating 'positive lasting memories' by developing and selling products that solve maintenance and cleaning problems. Built around the legendary WD-40 Multi-Use Product, the company operates an asset-light business model, focusing on brand management and innovation while utilizing a network of contract manufacturers to deliver solutions across the Americas, EIMEA, and Asia-Pacific.
Read more on WDFC →